Ensysce Biosciences Inc. (ENSC) Forward Price-to-Revenue Multiple

Graphic logo of Ensysce (ENSC)

Ensysce Biosciences (ENSC) is mitigating ESG risks through the development of abuse-deterrent medications and bioethical compliance. The company's expected P/S ratio demonstrates a fundamental trend where the value of 1.70 aligns with the current metric. High scalability potential is driven by global revenue from proprietary formulas. A unique gastrointestinal drug activation mechanism effectively protects the business from competitors' pricing pressure.

ENSC Ensysce Biosciences, Inc.: Market Cap to Expected Sales Ratio in the range 06/18/2023 - 11/13/2026

ENSC (ensysce.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Ensysce Biosciences, Inc.|ENSC - Analyst Median Target
- market capitalization details:
Market Valuation Ensysce Biosciences, Inc.|ENSC - Total Enterprise Value
- business book valuation details:
Net Assets per Single Share Ensysce Biosciences|ENSC - Book Valuation of Business|Market Capitalization to Book Value Ratio ensysce.com|ENSC - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Ensysce Biosciences|ENSC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Ensysce Biosciences, Inc.|ENSC - Aggregate Debt Obligations|Debts to Book Capitalization Ensysce Biosciences, Inc.|ENSC - Company Long-Term Debt|Company Short-Term Debts Ensysce Biosciences|Quick Liquidity ensysce.com
- business earnings and investment ratios data:
ENSC - Company Net Income|Expected Profit Ensysce Biosciences|ENSC - Business Payback Period|Forward P/E Multiple Ensysce Biosciences, Inc.|ENSC - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Ensysce Biosciences, Inc.|ENSC - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Ensysce Biosciences|ENSC - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months ensysce.com|ENSC - Earnings per share growth this year|Earnings growth forecast for next year Ensysce Biosciences
- sales volume and revenue indicators:
ENSC - Company Sales|Projected Sales Volume Ensysce Biosciences, Inc.|ENSC - Price to Sales|Price-to-Projected Revenue Ratio Ensysce Biosciences, Inc.
Summary company analysis:Ensysce ENSC
Product sample of Ensysce Biosciences Inc.

To assess the value of the innovative TAAP and MPAR platforms from Ensysce Biosciences (ENSC), utilize the expected P/S dynamics, which currently stands at 1.70. This indicator compares market capitalization with projected annual revenue, allowing investors to evaluate the sensitivity of share prices to potential cash gaps and the company's debt load prior to the publication of official financial statements.

Who Ensysce Biosciences competes with

Price-to-Projected Revenue Ratio Indivior INDV|Market Cap to Expected Sales Ratio Collegium Pharma (COLL)|CRON: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Canopy Growth Corp.|High Tide Inc. (HITI) - Price-to-Projected Revenue Ratio|ACB - Market Cap to Expected Sales Ratio|ACHV (Achieve Life Sciences, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Skye Bioscience Inc. (SKYE)|Forward P/S Multiple ANEB|INCR - Market Cap to Future Revenue Ratio|Nutriband - Forward Price-to-Revenue Multiple|Forward Price to Sales NSRX|IGC Pharma Inc - Forward P/S Multiple|MIRA: Price-to-Projected Revenue Ratio|FLGC: Forward P/S Multiple|IMCC - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adial Pharmaceuticals Inc.|Market Cap to Future Revenue Ratio Artelo ARTL|Price-to-Projected Revenue Ratio Titan Pharmaceuticals (TTNP)|Market Cap to Expected Sales Ratio Greenlane Holdings, Inc.|Forward P/S Multiple INM (InMed Pharma)|AKAN - Forward Price-to-Revenue Multiple|Enveric Biosciences - Forward P/S Multiple|Market Cap to Expected Sales Ratio Bright Green BGXX|HPCO: Forward P/S Multiple